SGBio Unveils First Microneedle Product 'SGDew Dermalizen' Trouble Patch

SGBio 'SGDew Dermalizen'
Photo by SGBio

[Asia Economy Reporter Lee Gwanju] CG Bio unveiled the 'CGDew DERMAREGEN' skin trouble care patch, the first product in its microneedle pipeline, on the 14th.

Microneedles are a transdermal drug delivery system that uses micro-needles within a few hundred micrometers in length to penetrate the skin's stratum corneum and directly deliver active ingredients to the dermis layer.

CG Bio's microneedle products have introduced a new mold packaging method through a patented process to enhance safety and demonstrate excellent efficacy. In particular, the so-called 'needle-mold integrated packaging' process, which uses a disposable plastic mold directly as packaging material, prevents the needles from being exposed to air during manufacturing, thereby reducing the possibility of contamination.

CGDew DERMAREGEN contains ingredients such as Zinc PCA, which helps with antibacterial action and sebum secretion reduction, Houttuynia cordata extract, and allantoin and panthenol, which have anti-inflammatory and wound healing effects. Additionally, the included tweezers allow users to pick up the patch and apply it to the skin more conveniently and hygienically.

CG Bio plans to officially launch DERMAREGEN in the first half of next year, followed by a total of three functional line patches including anti-aging care and whitening/blemish care. By 2025, the company aims to sequentially release veterinary pharmaceuticals and human pharmaceuticals.

Yoo Hyunseung, CEO of CG Bio, stated, "DERMAREGEN delivers active ingredients more efficiently to the skin compared to conventional topical cosmetics because it is absorbed directly into the dermis through microneedles," adding, "We will develop competitive market-leading products by applying patented microneedle technology to veterinary and human pharmaceuticals."

This content was produced with the assistance of AI translation services.